(Q53129637)

English

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.

scientific article published on 29 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

18

object named as

Jan Delabie

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

Marie Nordström

9

object named as

Marie Nordström

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

2

object named as

Arne Kolstad

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

4

object named as

Mats Jerkeman

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nils Hermann Nilsson-Ehle

14

object named as

Herman Nilsson-Ehle

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Christian Geisler

1

object named as

Christian H Geisler

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

21

object named as

Erkki Elonen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

5

object named as

Riikka Räty

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Marja-Liisa Karjalainen-Lindsberg

19

object named as

Marja-Liisa Karjalainen-Lindsberg

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Elisabeth Ralfkiaer

15

object named as

Elisabeth Ralfkiaer

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

16

object named as

Mats Ehinger

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Nordic Lymphoma Group

22

object named as

Nordic Lymphoma Group

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Mikael Eriksson

8

object named as

Mikael Eriksson

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Grete Fossum Lauritzsen

13

object named as

Grete F Lauritzsen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

10

object named as

Eva Kimby

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Lone Bredo Pedersen

7

object named as

Lone B Pedersen

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

author name string

Anna Laurell

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Niels S Andersen

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Hans Bentzen

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Outi Kuittinen

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Christer Sundström

17

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Peter Brown

20

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

language of work or name

0 references

publication date

29 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

158

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

355-362

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cyta

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09174.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2012.09174.X

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/22640180

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53129637&oldid=2068353750"